[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341844-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341844-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","overcoming-cancer-drug-resistance-with-nanoparticle-strategies-for-key-protein-inhibition","Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition","","Drug resistance remains a critical barrier in cancer therapy, weakening the effectiveness of chemotherapeutic, targeted, and immunotherapeutic agents. Overexpression of proteins such as Bcl-2, IAPs, Akt, and P-gp promotes resistance by blocking apoptosis, boosting survival, and expelling drugs. Despite availability of protein inhibitors, clinical translation is limited by systemic toxicity, poor bioavailability, and resistance emergence. Nanoparticle delivery improves solubility, stability, and tumor targeting via the EPR effect. Co-encapsulation can coordinate pharmacokinetics and pharmacodynamics. This review summarizes resistance mechanisms, inhibitor limitations, and nanoparticle advantages for improved outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/overcoming-cancer-drug-resistance-with-nanoparticle-strategies-for-key-protein-inhibition/341844/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/overcoming-cancer-drug-resistance-with-nanoparticle-strategies-for-key-protein-inhibition/341844.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does drug resistance reduce cancer therapy effectiveness?","Question",{"text":63,"@type":64},"Drug resistance diminishes the efficacy of standard doses. Increasing dose can raise non-specific toxicity and worsen patient burden.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do cancer cells acquire resistance against anticancer drugs?",{"text":68,"@type":64},"They can develop resistance through genetic mutations, overexpress specific resistance-related proteins, or hyperactivate drug efflux pumps that remove drugs from cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages do nanoparticle strategies provide for overcoming resistance?",{"text":72,"@type":64},"Nanoparticles can enhance drug solubility and stability while improving targeted delivery to tumors through the EPR effect, reducing off-target toxicity and potentially increasing therapeutic efficacy. Co-encapsulation may also help coordinate pharmacokinetic and pharmacodynamic profiles.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341844,1790147570,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","molecules   \nReview  \nOvercoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition  \nHyeonji Yoo†, Yeonjin Kim†, Jinseong Kim, Hanhee Cho and Kwangmeyung Kim *  \nCitation: Yoo, H.; Kim, Y.; Kim, J.; Cho, H.; Kim, K. Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition. Molecules 2024, 29, 3994. [https://](https://)[ ](https://)[doi.org/10.3390/molecules29173994](doi.org/10.3390/molecules29173994)  \nAcademic Editor: Keykavous Parang  \nReceived: 25 June 2024  \nRevised: 6 August 2024  \nAccepted: 21 August 2024  \nPublished: 23 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760,  \nRepublic of Korea; [mary927@ewhain.net](mary927@ewhain.net) (H.Y.); [duswls223@ewhain.net](duswls223@ewhain.net) (Y.K.); [jinseong@ewha.ac.kr](jinseong@ewha.ac.kr) (J.K.);  \n[ricky@ewha.ac.kr](ricky@ewha.ac.kr) (H.C.)  \n* Correspondence: [kimkm@ewha.ac.kr](kimkm@ewha.ac.kr)  \n† These authors contributed equally to this work.  \nAbstract: Drug resistance remains a critical barrier in cancer therapy, diminishing the effectiveness of chemotherapeutic, targeted, and immunotherapeutic agents. Overexpression of proteins such as B-cell lymphoma 2 (Bcl-2), inhibitor of apoptosis proteins (IAPs), protein kinase B (Akt), and P-glycoprotein (P-gp) in various cancers leads to resistance by inhibiting apoptosis, enhancing cell survival, and expelling drugs. Although several inhibitors targeting these proteins have been developed, their clinical use is often hampered by systemic toxicity, poor bioavailability, and resistance development. Nanoparticle-based drug delivery systems present a promising solution by improving drug solubility, stability, and targeted delivery. These systems leverage the Enhanced Permeation and Retention (EPR) effect to accumulate in tumor tissues, reducing off-target toxicity and increasing therapeutic efficacy. Co-encapsulation strategies involving anticancer drugs and resistance inhibitors within nanoparticles have shown potential in achieving coordinated pharmacokinetic and pharmacodynamic profiles. This review discusses the mechanisms of drug resistance, the limitations of current inhibitors, and the advantages of nanoparticle delivery systems in overcoming these challenges. By advancing these technologies, we can enhance treatment outcomes and move towards more effective cancer therapies.  \nKeywords: drug resistance; nanoparticle; drug delivery system; cancer therapy; targeted therapy  \n1. Introduction  \nIn current oncology, ongoing efforts to completely eradicate cancer have led to advancements in chemotherapy, targeted therapy, and immunotherapy [1–3] . Despite these advancements, a persistent challenge remains, specifically drug resistance [1,4–6] . Resistance to the administered drugs reduces their efficacy at standard doses, and increasing the dosage to overcome resistance often results in non-specific toxicity, exacerbating patient suffering [2,7] . Currently, overcoming drug resistance typically involves developing new drugs each time resistance occurs, which is a highly inefficient approach [8,9] . Therefore, addressing drug resistance is a critical area that urgently needs improvement in the next generation of cancer therapeutics [10,11] .  \nTo address this issue, it is essential to first understand the mechanisms by which cancer cells acquire drug resistance, as they can develop resistance through various pathways [5,12]. When tumor cells are continuously exposed to anticancer agents, they may acquire resistance by undergoing genetic mutations [8,12","cbCainrhO0BunK2k","https://ap.wps.com/l/cbCainrhO0BunK2k","pdf",4975028,"English","# Introduction\n## Drug resistance as an obstacle in oncology\n## Mechanisms of acquired resistance\n## Limitations of current protein inhibitors\n## Need for safer, targeted delivery platforms\n## Nanoparticle-based delivery strategies","[{\"question\":\"Why does drug resistance reduce cancer therapy effectiveness?\",\"answer\":\"Drug resistance diminishes the efficacy of standard doses. Increasing dose can raise non-specific toxicity and worsen patient burden.\"},{\"question\":\"How do cancer cells acquire resistance against anticancer drugs?\",\"answer\":\"They can develop resistance through genetic mutations, overexpress specific resistance-related proteins, or hyperactivate drug efflux pumps that remove drugs from cells.\"},{\"question\":\"What advantages do nanoparticle strategies provide for overcoming resistance?\",\"answer\":\"Nanoparticles can enhance drug solubility and stability while improving targeted delivery to tumors through the EPR effect, reducing off-target toxicity and potentially increasing therapeutic efficacy. Co-encapsulation may also help coordinate pharmacokinetic and pharmacodynamic profiles.\"}]","Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition | PDF",1790044152,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae518cc1d2be43490f917829105fe5e4.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a1c27f3e3c04811edf5178b7ea98faf.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/890fbf394e35c20ed39377343e3d30f4.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f240f4072d92b2a7d52b4c7fa2004cf2.webp",980,1385]